Bernu Kliniska Universitates Slimnica VSIA

The Bernu Kliniska Universitates Slimnica VSIA site in Riga is running a broad set of studies in digestive system diseases, neoplasms, nervous system diseases, and other major therapeutic areas. Much of the work focuses on children and adolescents, with trials aimed at testing new treatments, improving symptom control, and refining care for conditions seen in surgical and hospital settings.

• Studies in acute appendicitis are looking at better ways to manage uncomplicated cases and improve early diagnosis.
• Research in acute myeloid leukemia is evaluating new approaches for newly diagnosed pediatric patients.
• Several trials are exploring treatment options for asthma, allergic rhinoconjunctivitis, and chronic inducible urticaria.
• Other projects focus on multiple sclerosis, epileptic encephalopathies, and Dravet syndrome to assess effectiveness and long-term safety.

This mix of studies shows a strong emphasis on pediatric care, with research spanning oncology, neurology, allergy, and surgery-related conditions.

The site is contributing to clinical research in neoplasms, especially acute myeloid leukemia in children and adolescents. These studies are designed to test whether new treatment strategies can improve disease control while maintaining acceptable safety in young patients.

• Investigations in pediatric AML are assessing new therapy combinations for stronger anti-leukemic effect.
• Some research is focused on patients with FLT3-ITD-positive AML to see whether targeted treatment can improve response.
• Work in this area also includes measuring early treatment benefit and longer-term outcomes after standard therapy.

These trials reflect a focused effort to advance pediatric cancer care through more effective and better-tolerated treatment options.

Clinical trials in nervous system diseases at this hospital are centered on children with multiple sclerosis, Dravet syndrome, developmental and epileptic encephalopathies, and related seizure disorders. The main goal is to evaluate therapies that may reduce relapses, improve seizure control, and support long-term safety in pediatric patients.

• Research in pediatric multiple sclerosis is comparing treatment options to help lower relapse rates.
• Studies in Dravet syndrome and DEE are examining whether new therapies can reduce seizure frequency.
• Additional work is tracking the safety and tolerability of these medicines over time.

These studies highlight an active program in pediatric neurology, with attention to both symptom relief and durable treatment benefit.

Another important area at Bernu Kliniska Universitates Slimnica VSIA is hormonal diseases, especially conditions affecting childhood growth. Trials are evaluating therapies for growth hormone deficiency, small for gestational age children, Turner syndrome, Noonan syndrome, and idiopathic short stature.

• These studies aim to compare treatments that may support healthier growth in children with short stature.
• Research is also focused on confirming whether newer options perform as well as established growth therapies.
• The work includes children with different causes of growth delay, reflecting a broad pediatric endocrine program.

Overall, this research area is centered on improving growth outcomes and treatment convenience for young patients and their families.

The site also supports trials in immune system diseases and respiratory tract diseases, including asthma, birch pollen-induced allergic rhinoconjunctivitis, and chronic inducible urticaria. These studies are designed to test new ways to ease symptoms and improve day-to-day disease control.

• Research in allergic rhinoconjunctivitis is evaluating whether allergen-based treatment can reduce seasonal symptoms.
• Asthma studies are looking at rescue treatment approaches to help prevent severe flare-ups.
• Work in chronic inducible urticaria is assessing therapies for patients whose symptoms remain difficult to control.

This area shows a practical focus on better symptom management across common allergic and inflammatory conditions.

Additional studies at the site address pathological conditions, signs and symptoms such as neurogenic detrusor overactivity, lower limb spasticity caused by cerebral palsy, and acute bacterial skin and skin structure infections. These trials are focused on improving comfort, function, and infection management in pediatric patients.

• Trials in neurogenic bladder dysfunction are exploring better symptom control for children with urinary problems.
• Research in spasticity is examining whether treatment can reduce muscle stiffness and improve mobility.
• In skin infections, the goal is to assess safer and more effective treatment options for children.

These studies reflect a broad hospital-based effort to address common and complex pediatric conditions through improved supportive and therapeutic care.